Fisher Asset Management LLC Buys 82,250 Shares of DexCom, Inc. (NASDAQ:DXCM)

Fisher Asset Management LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 10.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 856,124 shares of the medical device company’s stock after acquiring an additional 82,250 shares during the period. Fisher Asset Management LLC owned about 0.22% of DexCom worth $57,395,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Capital Insight Partners LLC increased its position in shares of DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares during the last quarter. HM Payson & Co. raised its stake in shares of DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after acquiring an additional 100 shares in the last quarter. Clear Creek Financial Management LLC lifted its holdings in shares of DexCom by 4.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after acquiring an additional 120 shares during the last quarter. SeaCrest Wealth Management LLC boosted its stake in shares of DexCom by 3.6% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock valued at $501,000 after purchasing an additional 152 shares in the last quarter. Finally, Securian Asset Management Inc. grew its holdings in shares of DexCom by 0.7% during the 2nd quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after purchasing an additional 161 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DXCM. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Leerink Partners dropped their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Wells Fargo & Company boosted their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Stifel Nicolaus raised their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Up 6.9 %

Shares of NASDAQ:DXCM opened at $77.83 on Tuesday. The firm has a market capitalization of $30.40 billion, a P/E ratio of 46.60, a P/E/G ratio of 2.23 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a 50 day moving average price of $70.76 and a 200-day moving average price of $88.93. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.